Fact sheet: BlackRock GF Wld Hlt Sci

Fund information
Fund name
BlackRock GF World Healthscience A2 USD
Fund manager company
BlackRock (Luxembourg) S.A.
Fund type
Offshore Fund
Fund managers
  • Thomas Callensince 31/03/2011
  • Erin Xiesince 31/03/2011
Fund objective
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund's assets. The Fund invests globally at least 70% of its total assets in the shares of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
Benchmark
  • MSCI World Healthcare
Investment style
None
Investment method
Shares
Quick stats
1 Year return
-7.6%
1 Year rank in sector
10/31
Sector
FO Equity - Pharma Health & Biotech
Yield
-
Ongoing charge (OCF)
?A fund’s ongoing charges figure (OCF) is similar to the old-style total expense ratio. It reflects the annual charge to investors in the fund, in percentage terms, but does not include extra performance-related fees (where these are levied) or the fund’s trading expenses on its underlying investments.
1.81%
Fund size
£2,884m (£3,677m last year)
FE Risk score
?FE Risk Scores measure the riskiness of instruments relative to the FTSE 100 index of shares. Weekly volatility is measured over three years with recent behaviour counting more heavily than earlier behaviour. Cash-type investments will have scores close to zero. Funds will tend to have scores in the 0-150 range. The FTSE 100 is always scored at 100. There is no upper limit.
121
Top in this sector
Fund name1 Year
Pictet Health5.2%
Fidelity Gbl Health Care4.5%
Variopartner SICAV MVGbMdtcF2%
BB Medtech1.3%
Wellington GlHthcr LS-1%
...more in FO Equity - Pharma Health & Biotech

Performance snapshot

Holdings snapshot

  • USA73%
    Switzerland6.3%
    Money Market6%
    UK5.2%
    Japan2.5%
  • Pharmaceuticals39.2%
    Healthcare & Medical Products19.2%
    Biotechnology/Medical17.8%
    Health Care17.8%
    Money Market6%
  • US Equities73%
    Swiss Equities6.3%
    Money Market6%
    UK Equities5.2%
    Japanese Equities2.5%

Performance vs Sector

Cumulative performance
 1 mth3 mth6 mth1 yr3 yr5 yr
Fund0.8%-6.1%-4.9%-7.6%20.4%101.8%
Sector2.4%-3%-1%-9.4%26%109.7%
Rank within sector23 / 3227 / 3224 / 3210 / 3118 / 2519 / 24
Quartile3rd4th3rd2nd3rd4th
Calendar performance
 YTD - 20162015201420132012
Fund-8.5%4.6%24.4%43.1%16.9%
Sector-9.4%7.2%28.1%41%16.7%
Rank within sector10 / 3123 / 2920 / 2611 / 2416 / 24
Quartile2nd4th4th2nd3rd
Risk statistics
Alpha
?Alpha is a measure of a fund's over- or under-performance by comparison to its benchmark. If the Alpha is 5, the fund has outperformed its benchmark by 5%; so the greater the Alpha, the greater the outperformance.
-0.02
Beta
?Beta estimates a fund's volatility by comparison to that of its benchmark. A fund with a beta close to 1 means that the fund will move generally in line with the benchmark. Higher than 1 and the fund is more volatile than the benchmark and vice versa.
0.83
Sharpe
?This commonly-used measure calculates the level of return over and above the return of a notional risk-free investment, such as cash. The difference in returns is then divided by the fund's volatility. The resulting ratio is an indication of the amount of excess return generated per unit of risk.
0.27
Volatility
?Volatility (or standard deviation), when applied to an investment fund, expresses its risk. It shows how widely a range of returns varied from the fund's average return over a particular period. For example, if a fund had an average return of 5%, and its volatility was 15, this would mean that the range of its returns over the period had swung between +20% and -10%.
14.09
Tracking error
?This measures the standard deviation of a fund's excess returns over the returns of an index or benchmark portfolio. As such, it can be an indication of 'riskiness' in the manager's investment style. A Tracking Error below 2 suggests a passive approach. At 3 and above the the manager will be deploying a more active investment style.
4.87
Information ratio
?This is a useful risk-adjusted measure of actively managed fund performance. It is calculated by deducting the returns of the fund's benchmark from the fund's overall returns, then dividing the result by its tracking error. The higher the Information Ratio the better. It is generally considered that a figure of 0.5 reflects a good performance, 0.75 very good, and 1.00 outstanding.
-0.27
R-Squared
?An indication of how closely correlated a fund is to an index or a benchmark. Values for R-Squared range between 0 and 1, with 0 indicating no correlation at all and 1 showing a perfect match. Values upwards of 0.7 suggest that the fund's behaviour is increasingly linked to its benchmark.
0.92
Price movement
52 week high35.88
52 week low30.02
Current bid price-
Current offer price-
Current mid price32.28
Region
1USA72.96%
2Switzerland6.25%
3Money Market5.97%
4UK5.16%
5Japan2.5%
6France2.23%
7Germany1.93%
8Israel1.37%
9Australia0.53%
Industry sector
1Pharmaceuticals39.18%
2Healthcare & Medical Products19.21%
3Biotechnology/Medical17.84%
4Health Care17.8%
5Money Market5.97%
Asset type
1US Equities72.96%
2Swiss Equities6.25%
3Money Market5.97%
4UK Equities5.16%
5Japanese Equities2.5%
6French Equities2.23%
7German Equities1.93%
8Israeli Equities1.37%
9Australian Equities0.53%
Individual holdings
1UNITEDHEALTH GROUP INC5.02%
2ROCHE HLDG AG4.78%
3MEDTRONIC INC4.65%
4PFIZER INC4.54%
5JOHNSON & JOHNSON3.66%
6AMGEN INC3.45%
7BOSTON SCIENTIFIC CORP2.61%
8ALLERGAN INC2.45%
9BAXTER INTERNATIONAL INC2.41%
Management
Fund manager group
BlackRock
Fund manager company
BlackRock (Luxembourg) S.A.
Fund type
Offshore Fund
Fund objective
The Fund aims to maximise the return on your investment through a combination of capital growth and income on the Fund's assets. The Fund invests globally at least 70% of its total assets in the shares of companies the main business of which is in healthcare, pharmaceuticals, medical technology and supplies and the development of biotechnology.
Benchmark
  • MSCI World Healthcare
Investment style
None
Investment method
Shares
Fund managers
NameSinceBiography
Thomas Callen31/03/2011Tom Callan, CFA, Managing Director and senior portfolio manager, is head of BlackRock's Global Opportunities equity team and a member of the Leadership Committee. He is architect of the team's investment process, leads the team's Investment Strategy Group, and provides portfolio and risk management oversight for all of the team's products. Prior to joining BlackRock's Global Opportunities equity team in 1996, Tom was with the PNC Asset Management Group, which he joined in 1992. He started as a health care analyst for PNC's mutual fund group and later served as an international equity analyst. Tom began his investment career at PNC Bank as a personal trust portfolio manager in 1988. Mr. Callan earned a BA degree in economics, with honors, from Boston College in 1981.
Erin Xie31/03/2011Erin Xie, PhD, Managing Director and portfolio manager, is a member of BlackRock's Global Opportunities team. She is lead portfolio manager for the healthcare sector, product manager for Health Sciences equity portfolios, and a member of the team's Investment Strategy Group. Erin's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Erin was a research associate with Sanford Bernstein covering the pharmaceutical industry. From 1994 until 1997, she was a Postdoctoral Research Scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from UCLA in 1993 and a MBA degree from the MIT Sloan School of Management in 1999.
Compliance
Transparent for Austrian Tax, Transparent for Swiss Tax, UCITS IV Compliant, MAS Unrestricted Scheme
Domicile
No data available.
Fund for sale in
Austria, Belgium, Bahrain, Brunei Darussalam, Switzerland, Chile, China, Czech Republic, Germany, Denmark, Spain, Finland, France, United Kingdom, Gulf Cooperation Council, Gibraltar, Greece, Guernsey, Hong Kong, Hungary, Ireland, Iceland, Italy, Jersey, Republic Of Korea, Luxembourg, Macau, Malta, Mauritius, Netherlands, Norway, Offshore, Poland, Portugal, Singapore, Slovakia, Sweden, Taiwan - Province Of China
BlackRock GF World Healthscience A2 EUR
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)1.81%
Bid price-
Offer price-
Mid price30.47
CurrencyEUR
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeM021
BlackRock GF World Healthscience A2 Hedged AUD
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.82%
Total expense ratio (TER)1.82%
Bid price-
Offer price-
Mid price11.32
CurrencyAUD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFHNN
BlackRock GF World Healthscience A2 Hedged CNH
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price87.03
CurrencyCNH
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFVPD
BlackRock GF World Healthscience A2 Hedged HKD
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.82%
Total expense ratio (TER)1.82%
Bid price-
Offer price-
Mid price114.12
CurrencyHKD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFJNV
BlackRock GF World Healthscience A2 Hedged SGD
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.82%
Total expense ratio (TER)1.84%
Bid price-
Offer price-
Mid price11.44
CurrencySGD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeFJCC
BlackRock GF World Healthscience A2 USD
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.81%
Total expense ratio (TER)1.81%
Bid price-
Offer price-
Mid price32.28
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeM024
BlackRock GF World Healthscience A5 Hedged AUD
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.82%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price10.65
CurrencyAUD
Price updated25/02/2015
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeFQUZ
BlackRock GF World Healthscience A5 USD
Initial charge5%
Annual charge1.5%
Min single investment£5,000
Min regular saving£0
Available in ISANo
Ongoing charge (OCF)1.82%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price10.61
CurrencyUSD
Price updated25/02/2015
TypeIncome
Institutional or retail classRetail
Domicile-
Citi codeFQUY
BlackRock GF World Healthscience C2 EUR
Initial charge-
Annual charge2.75%
Min single investment£5,000
Min regular saving£800
Available in ISANo
Ongoing charge (OCF)3.07%
Total expense ratio (TER)-
Bid price-
Offer price-
Mid price25.27
CurrencyEUR
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMT92
BlackRock GF World Healthscience C2 USD
Initial charge-
Annual charge2.75%
Min single investment£5,000
Min regular saving£800
Available in ISANo
Ongoing charge (OCF)3.07%
Total expense ratio (TER)3.07%
Bid price-
Offer price-
Mid price26.78
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMP86
BlackRock GF World Healthscience D2 EUR
Initial charge5%
Annual charge0.75%
Min single investment£100,000
Min regular saving£10,000
Available in ISANo
Ongoing charge (OCF)1.06%
Total expense ratio (TER)1.07%
Bid price-
Offer price-
Mid price32.64
CurrencyEUR
Price updated01/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeF36B
BlackRock GF World Healthscience D2 USD
Initial charge5%
Annual charge0.75%
Min single investment£100,000
Min regular saving£1,000
Available in ISANo
Ongoing charge (OCF)1.06%
Total expense ratio (TER)1.07%
Bid price-
Offer price-
Mid price34.59
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeBND4
BlackRock GF World Healthscience E2 EUR
Initial charge3%
Annual charge2%
Min single investment£5,000
Min regular saving£800
Available in ISANo
Ongoing charge (OCF)2.32%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price28.21
CurrencyEUR
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMV62
BlackRock GF World Healthscience E2 USD
Initial charge3%
Annual charge2%
Min single investment£5,000
Min regular saving£800
Available in ISANo
Ongoing charge (OCF)2.32%
Total expense ratio (TER)2.31%
Bid price-
Offer price-
Mid price29.9
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classRetail
Domicile-
Citi codeMV61
BlackRock GF World Healthscience X2 USD
Initial charge-
Annual charge-
Min single investment£10,000,000
Min regular saving£800
Available in ISANo
Ongoing charge (OCF)0.06%
Total expense ratio (TER)0.05%
Bid price-
Offer price-
Mid price36.58
CurrencyUSD
Price updated01/12/2016
TypeAccumulation
Institutional or retail classInstitutional
Domicile-
Citi codeHGJ5
Data provided by

The Content is only for your general information and use and is not intended to address your particular requirements. The Content does not constitute any form of advice, recommendation or arrangement by Moneywise and is not intended to be relied upon by you in making (or refraining from making) any specific investment or other decisions. Appropriate independent advice should be obtained before making any such decision.

This information is sourced from our partner Financial Express. We believe the data to be correct however you should take care in using any information.

You should be aware that prices may fall as well as rise and that the income derived can go down as well as up. When buying or selling any investment that fluctuates in price or value you may get back less than you invested. Past performance is not necessarily a guide to future performance.